Lainie P. Martin

Oncology

3400 Civic Center Boulevard
West Pavilion, 3rd Floor
Philadelphia, PA 19104

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 71 publications

PTEN deficiency confers sensitivity to ATR inhibitor-based treatment in high-grade serous ovarian cancer.

PTEN deficiency confers sensitivity to ATR inhibitor-based treatment in high-grade serous ovarian cancer.

Journal: The Journal of clinical investigation

Published: July 07, 2026

Incidence of ESR1 gene mutations among patients with endometrioid endometrial cancer.

Incidence of ESR1 gene mutations among patients with endometrioid endometrial cancer.

Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

Published: September 17, 2025

Approaches to optimize the benefits of immunotherapy and immunotherapy combinations across endometrial cancer types.

Approaches to optimize the benefits of immunotherapy and immunotherapy combinations across endometrial cancer types.

Journal: Journal of the National Cancer Institute

Published: August 13, 2025

A phase II, randomized, double-blind study of the use of rucaparib vs. placebo maintenance therapy in metastatic and recurrent endometrial cancer.

A phase II, randomized, double-blind study of the use of rucaparib vs. placebo maintenance therapy in metastatic and recurrent endometrial cancer.

Journal: Gynecologic oncology

Published: May 12, 2025

Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with pembrolizumab in patients with platinum-resistant ovarian cancer.

Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with pembrolizumab in patients with platinum-resistant ovarian cancer.

Journal: Gynecologic oncology

Published: April 05, 2025

Rucaparib maintenance for newly diagnosed advanced ovarian cancer: interim overall survival, progression-free survival, and safety at 5 years of follow-up from the phase III ATHENA-MONO/GOG-3020/ENGOT-ov45 study.

Rucaparib maintenance for newly diagnosed advanced ovarian cancer: interim overall survival, progression-free survival, and safety at 5 years of follow-up from the phase III ATHENA-MONO/GOG-3020/ENGOT-ov45 study.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: October 28, 2024

NCCN Guidelines® Insights: Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer, Version 3.2024.

NCCN Guidelines® Insights: Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer, Version 3.2024.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: October 16, 2024

Patient-reported outcomes from the MIRASOL trial evaluating mirvetuximab soravtansine versus chemotherapy in patients with folate receptor α-positive, platinum-resistant ovarian cancer: a randomised, open-label, phase 3 trial.

Patient-reported outcomes from the MIRASOL trial evaluating mirvetuximab soravtansine versus chemotherapy in patients with folate receptor α-positive, platinum-resistant ovarian cancer: a randomised, open-label, phase 3 trial.

Journal: The Lancet. Oncology

Published: September 06, 2024

Real-world impact of the platinum chemotherapy shortage on US patients with advanced cancer.

Real-world impact of the platinum chemotherapy shortage on US patients with advanced cancer.

Journal: Journal of the National Cancer Institute

Published: August 30, 2024

Phase I and Randomized Phase II Study of Ruxolitinib With Frontline Neoadjuvant Therapy in Advanced Ovarian Cancer: An NRG Oncology Group Study.

Phase I and Randomized Phase II Study of Ruxolitinib With Frontline Neoadjuvant Therapy in Advanced Ovarian Cancer: An NRG Oncology Group Study.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: May 22, 2024

Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer.

Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer.

Journal: The New England journal of medicine

Published: December 06, 2023

Phase 1b study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate, in combination with carboplatin and bevacizumab in patients with platinum-sensitive ovarian cancer.

Phase 1b study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate, in combination with carboplatin and bevacizumab in patients with platinum-sensitive ovarian cancer.

Journal: Gynecologic oncology

Published: November 29, 2023

Showing 1-12 of 71

Last Updated: 09/26/2026